Millennium Management’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Millennium Management’s Portfolio PEAR Stock Details PEAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-24,204	Closed	-$49K	–	7344
2022 Q3	$49K	Sell	24,204 -224,195	-90%	-$380K	﹤0.01%	6196
2022 Q2	$383K	Buy	248,399 +211,551	+574%	+$827K	﹤0.01%	5165
2022 Q1	$186K	Buy	+36,848	New	+$167K	﹤0.01%	5854
2021 Q4	–	Sell	-1,209,164	Closed	-$12M	–	7615
2021 Q3	$12M	Buy	1,209,164 +484,035	+67%	+$4.79M	0.01%	1830
2021 Q2	$7.16M	Buy	+725,129	New	+$7.11M	﹤0.01%	2298

Other funds holding PEAR

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

SGA

SB Global Advisers London, United Kingdom $861M AUM 71.72% 1-Year Est. Return

Arboretum Ventures Ann Arbor, Michigan $1.72M AUM 82.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TAA

TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Palantir Technologies Denver, Colorado $9.72M AUM 6.46% 1-Year Est. Return

Millennium Management's PEAR Position: Q4 2022 in Review

Millennium Management sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q4 2022, closing a stake of 24,204 shares — an estimated $49K sold.

Millennium Management first reported a position in PEAR in Q2 2021 and held it in 5 quarters. The position peaked at $12M in Q3 2021. 64 funds tracked by Wall St. Rank hold PEAR as of Q4 2022.

Millennium Management reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q4 2022 after selling out during the quarter.
Millennium Management sold 24,204 Pear Therapeutics, Inc. Class A Common Stock shares in Q4 2022, an estimated $49K.
Millennium Management first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q2 2021 and held it in 5 quarters.
Millennium Management's Pear Therapeutics, Inc. Class A Common Stock position peaked at $12M in Q3 2021.
64 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q4 2022.

Based on Millennium Management's 13F filing for Q4 2022, filed 14 Feb 2023.